Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI110793

Electrical Charge. ITS ROLE IN THE PATHOGENESIS AND PREVENTION OF EXPERIMENTAL MEMBRANOUS NEPHROPATHY IN THE RABBIT

Sharon G. Adler, Haiyen Wang, Harry J. Ward, Arthur H. Cohen, and Wayne A. Border

University of California at Los Angeles School of Medicine, Department of Medicine, Harbor-UCLA Medical Center, Torrance, California 90509

University of California at Los Angeles School of Medicine, Department of Pathology, Harbor-UCLA Medical Center, Torrance, California 90509

University of Utah School of Medicine, Department of Medicine, Salt Lake City, Utah 84132

Find articles by Adler, S. in: PubMed | Google Scholar

University of California at Los Angeles School of Medicine, Department of Medicine, Harbor-UCLA Medical Center, Torrance, California 90509

University of California at Los Angeles School of Medicine, Department of Pathology, Harbor-UCLA Medical Center, Torrance, California 90509

University of Utah School of Medicine, Department of Medicine, Salt Lake City, Utah 84132

Find articles by Wang, H. in: PubMed | Google Scholar

University of California at Los Angeles School of Medicine, Department of Medicine, Harbor-UCLA Medical Center, Torrance, California 90509

University of California at Los Angeles School of Medicine, Department of Pathology, Harbor-UCLA Medical Center, Torrance, California 90509

University of Utah School of Medicine, Department of Medicine, Salt Lake City, Utah 84132

Find articles by Ward, H. in: PubMed | Google Scholar

University of California at Los Angeles School of Medicine, Department of Medicine, Harbor-UCLA Medical Center, Torrance, California 90509

University of California at Los Angeles School of Medicine, Department of Pathology, Harbor-UCLA Medical Center, Torrance, California 90509

University of Utah School of Medicine, Department of Medicine, Salt Lake City, Utah 84132

Find articles by Cohen, A. in: PubMed | Google Scholar

University of California at Los Angeles School of Medicine, Department of Medicine, Harbor-UCLA Medical Center, Torrance, California 90509

University of California at Los Angeles School of Medicine, Department of Pathology, Harbor-UCLA Medical Center, Torrance, California 90509

University of Utah School of Medicine, Department of Medicine, Salt Lake City, Utah 84132

Find articles by Border, W. in: PubMed | Google Scholar

Published March 1, 1983 - More info

Published in Volume 71, Issue 3 on March 1, 1983
J Clin Invest. 1983;71(3):487–499. https://doi.org/10.1172/JCI110793.
© 1983 The American Society for Clinical Investigation
Published March 1, 1983 - Version history
View PDF
Abstract

Intravenous cationic bovine serum albumin (BSA, pI > 9.5) induces membranous nephropathy in immunized rabbits. In this study, unimmunized rabbits received intravenous injections of cationic (n = 3) or native (n = 3) or native (n = 3) BSA, followed by ex vivo isolated left renal perfusions with sheep anti-BSA antibody. Capillary wall deposits of IgG and C3 were seen exclusively in the group receiving cationic BSA, confirming an in situ pathogenesis for cationic, BSA-induced membranous nephropathy, and demonstrating the importance of a cationic antigen for its production. We then explored whether membranous nephropathy in this model is prevented by the concomitant injection of protamine sulfate, a filterable, relatively non-immunogenic polycation. An in vitro study demonstrated that protamine sulfate incubated with glomerular basement membrane (GBM) decreased the subsequent binding of radiolabeled cationic BSA (P < 0.05). In vivo, protamine sulfate was shown to bind to anionic sites in the glomerular capillary wall after intravenous injection.

Groups of rabbits received 3 wk of daily intravenous injections of cationic BSA alone (n = 15) or cationic BSA and protamine (n = 18). After 2 wk of injection of cationic BSA alone, typical membranous nephropathy developed. Granular deposits of IgG and C3 were present along the GBM associated with subepithelial dense deposits, foot process effacement, and marked albuminuria. Protamine significantly reduced or prevented the formation of deposits (P < 0.001) and in6 of 18 protamine-treated animals, existing deposits decreased or disappeared between 2 and 3 wk of injection. Albuminuria was significantly reduced in protamine-treated animals with a mean of 124±55 mg/24 h compared to 632±150 mg/24 h in the control group receiving cationic BSA alone. No significant differences between the groups were noted in serum lev9lsof IgG, C3, anti-BSA antibody, or circulating immune complex size. Studies in additional animals (n = 5) given radiolabeled cationic BSA showed that protamine did not alter the clearance of cationic BSA from serum.

Control experiments showed that protamine's beneficial effects were not related to its weak anticoagulant property or toits theoretical ability to deplete tissue histamine. The administration of heparin (n = 6) or diphenhydramine (n = 6) had no effect on the development of the epimembranous lesion compared to the group receiving cationic BSA alone. In addition, homogenized whole kidney histamine content was not significantly different in the group receiving cationic BSA alone compared to the group receiving cationic BSA and protamine.

This work shows that a cationic BSA-induced glomerular lesion can be produced by a renal perfusion technique involving in situ complex formation and that this process requires a cationic antigen for its development. We believe that the demonstrated beneficial effects of protamine are due to its ability to bind to glomerular anionic sites, and that this electrostatic interaction results in inhibition for the further binding of the cationic antigen, thereby limiting the severity of glomerulonephritis in this model.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 487
page 487
icon of scanned page 488
page 488
icon of scanned page 489
page 489
icon of scanned page 490
page 490
icon of scanned page 491
page 491
icon of scanned page 492
page 492
icon of scanned page 493
page 493
icon of scanned page 494
page 494
icon of scanned page 495
page 495
icon of scanned page 496
page 496
icon of scanned page 497
page 497
icon of scanned page 498
page 498
icon of scanned page 499
page 499
Version history
  • Version 1 (March 1, 1983): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts